Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | PPARG | P37231 | 5/20 | 0.73 |
| ▸ | F7 | P08709 | 4/20 | 0.73 |
| ▸ | F3 | P13726 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.73 |
| ▸ | PPARD | Q03181 | 4/20 | 0.73 |
| ▸ | PPARA | Q07869 | 4/20 | 0.73 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.73 |
| ▸ | FABP3 | P05413 | 3/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.73 |
| ▸ | FABP4 | P15090 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.73 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18325614 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL15908483 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL15908480 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL2621471 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL15908489 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL15908476 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL11893268 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL9183242 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL21302754 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL10740192 | 0.98 | PPARG (0.72) | ALDH1A1PPARGF7F3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030104082-A1 | Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases | MCGINLEY PARTNERS, LLC (US) | 2003-06-05 | — | — | US | claimed |
| US-9662360-B2 | Treatment of herpes, pseudomonas, staph, and hepatitis | MERITUS CORPORATION (DM) | 2017-05-30 | — | — | US | disclosed |
| US-20160151436-A1 | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | MERITUS CORPORATION (DM) | 2016-06-02 | — | — | US | disclosed |
| WO-2012119781-A2 | NOVEL LIPIDS, PHOSPHOLIPIDS, PHOSPHOLIPID AND LIPID COMPOSITIONS AND THEIR USE | UNIVERSITY OF GENEVA (CH) | 2012-09-13 | — | — | WO | disclosed |
| US-20100303935-A1 | Medicinal Composition | MCGINLEY PARTNERS, LLC (US) | 2010-12-02 | — | — | US | disclosed |
| US-20090191288-A1 | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | SQUIRES MERYL J | 2009-07-30 | — | — | US | disclosed |
| US-7071233-B2 | Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases | Squires, Meryl J. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20030104082-A1 | Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases | MCGINLEY PARTNERS, LLC (US) | 2003-06-05 | — | — | US | disclosed |
| US-6350784-B1 | PHYTOCHEMICALS, SURFACTANT, FOLIC ACID, | Squires, Meryl J. | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151436-A1 | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | NISCH, CUTA, HRH1 | ALDH1A1 690/4885PPARG 1543/4885F7 767/4885 |
| US-20090191288-A1 | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | ASPH, KCNH3, PRPH | ALDH1A1 876/4885PPARG 979/4885F7 572/4885 |
| US-20100303935-A1 | Medicinal Composition | MUSK, TNNC1, ACHE | ALDH1A1 759/4885PPARG 842/4885F7 909/4885 |
| US-20030104082-A1 | Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases | CD14, CD59, SLC19A1 | ALDH1A1 1759/4885PPARG 2077/4885F7 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.